MacroGenics announced it made $18.7 million in sales last quarter, down from $53.0 million a year earlier.

Nov 13, 2026, 9:13 AM ETResultsRead the original at globenewswire.com

Neutral

MacroGenics' revenue fell to $18.7 million from $53.0 million as milestone income declined, and it reported a $20.1 million loss. Cash is expected to support operations through 2028, and MGC028 advanced, so the report does not clearly change the company's outlook.

MGNX · MacroGenics

AI read · Neutral

The AI's read

Lower milestone income explains the sales drop, and the quarter also ended with a $20.1 million loss. The company expects its cash and investments to fund operations through 2028. MGC028 has completed Phase 1 dose escalation, but its next study and interim update are still ahead. These facts point in different directions and do not clearly change the company's outlook.

Get alerts for MGNX

Follow MacroGenics (MGNX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for MGNX

Free on the App Store and Google Play, or on the web.